The Overview
Zealand Pharma reported positive topline results from its Phase 2 ZUPREME-2 trial for petrelintide, an amylin analog, in 220 participants with overweight or obesity and type 2 diabetes. The trial met its primary endpoint, showing statistically significant and clinically meaningful body weight reductions of up to 9.2% from baseline at week 28, compared to 2.0% with placebo. Petrelintide also demonstrated clinically relevant HbA1c reductions of up to 0.65% versus a 0.23% increase with placebo. The drug exhibited a favorable safety and tolerability profile, consistent with previous findings, with very low discontinuation rates due to gastrointestinal adverse events (1.9% for petrelintide vs. 1.7% for placebo).
Knolens Analysis
At a Glance
| Indication | overweight or obesity and type 2 diabetes |
| Drug | petrelintide |
| Mechanism of Action | amylin analog |
| Company | Zealand Pharma |
| Trial Phase | Phase 2 |
| Trial Acronym | ZUPREME-2 |
| NCT ID | NCT06926842 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Endocrinology & Metabolic Diseases |
| Primary Endpoint | percentage change in body weight from baseline to week 28 |
| Patient Population Size | 220 participants |
| Follow-up Duration | 28 weeks |
| Comparator | placebo |
| Mean Baseline BMI | 36.3 kg/m2 |
| Mean Baseline HbA1c | 8.0% |
| Co-development Partner | Roche |
| Gastrointestinal AE Discontinuation Rate | 1.9% for petrelintide versus 1.7% with placebo |
| Trial Location | United States |
| Secondary Endpoints | body weight loss of ≥5% and ≥10%, absolute change in body weight, change in waist circumference, change in hemoglobin A1c (HbA1c), change in high-sensitivity C-reactive protein (hsCRP), change in fasting glucose, and change in fasting lipids |
Zealand Pharma's Petrelintide Shows Strong Weight, HbA1c Reductions in Phase 2
Zealand Pharma reported positive topline results from its Phase 2 ZUPREME-2 trial for petrelintide, an amylin analog, in 220 participants with overweight or obesity and type 2 diabetes. The trial met its primary endpoint, showing statistically significant and clinically meaningful body weight reductions of up to 9.2% from baseline at week 28, compared to 2.0% with placebo. Petrelintide also demonstrated clinically relevant HbA1c reductions of up to 0.65% versus a 0.23% increase with placebo. The drug exhibited a favorable safety and tolerability profile, consistent with previous findings, with very low discontinuation rates due to gastrointestinal adverse events (1.9% for petrelintide vs. 1.7% for placebo).
- Petrelintide, administered once-weekly subcutaneously, led to a mean body weight reduction of up to 9.2% from baseline at week 28 across all three treatment arms, significantly outperforming placebo which showed a 2.0% reduction. This met the trial's primary endpoint, highlighting petrelintide's potential as a standalone treatment for chronic weight management in this patient population.
- Beyond weight loss, petrelintide demonstrated clinically relevant reductions in HbA1c, with participants achieving a placebo-adjusted reduction of 0.61%-0.88%. The safety profile was consistent with prior trials, showing no unexpected signals and a favorable tolerability profile comparable to placebo, with only 1.9% of petrelintide-treated participants discontinuing due to gastrointestinal adverse events.
- Building on these positive Phase 2 results, Zealand Pharma and Roche have initiated a Phase 3 registrational program for petrelintide. This program includes three trials (ZUPREME-3, ZUPREME-4, ZUPREME-5) targeting approximately 7,000 participants across various obesity and type 2 diabetes subpopulations, underscoring the companies' commitment to addressing unmet medical needs in chronic weight management.
Frequently Asked Questions
What is the mechanism of action of petrelintide for metabolic conditions like obesity and type 2 diabetes?
Petrelintide is designed to modulate key metabolic pathways involved in glucose homeostasis and energy balance. Its mechanism likely involves interaction with specific receptors that influence insulin secretion, glucagon suppression, gastric emptying, and satiety signals. This multifaceted approach aims to address the underlying pathophysiology of both conditions.
What is the potential clinical utility of petrelintide in managing overweight or obesity and type 2 diabetes?
Petrelintide holds promise for providing significant improvements in glycemic control and substantial weight reduction. Its therapeutic profile could offer a new option for patients who have not achieved adequate control with existing therapies or require a more comprehensive metabolic intervention. This could lead to better long-term outcomes and reduced comorbidity risk.
What are the key safety and tolerability considerations for petrelintide in patients with metabolic disorders?
As with many novel metabolic agents, potential safety considerations for petrelintide typically focus on gastrointestinal events, such as nausea, vomiting, or diarrhea, particularly during dose escalation. Monitoring for these and other systemic effects, including cardiovascular parameters or renal function, would be important. A thorough understanding of its long-term safety profile will be crucial for its clinical adoption.
How might petrelintide integrate into current treatment paradigms for overweight, obesity, and type 2 diabetes?
Petrelintide could serve as a valuable addition to the therapeutic armamentarium, potentially as a monotherapy or in combination with other agents. Its efficacy in both weight management and glycemic control suggests it could be particularly beneficial for patients with comorbid obesity and type 2 diabetes. This integration would depend on its comparative effectiveness, safety profile, and patient-specific needs.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
